ロード中...
Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2
Medical treatment has progressed significantly over the past decade towards achieving and maintaining clinical remission in patients with refractory ulcerative colitis (UC). Proposed mediators of inflammation in UC include pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interl...
保存先:
| 出版年: | World J Gastroenterol |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Baishideng Publishing Group Inc
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4528020/ https://ncbi.nlm.nih.gov/pubmed/26269667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i29.8776 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|